Given the DLBCL patients the front-line chemotherapy R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), compared to CD5− DLBCL, CD5+ DLBCL has an inferior survival rate, with a 5-year overall survival (OS) rate of only 35.5% [29]. Here, CD5 is linked to diffuse large B-cell lymphoma.